K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The goal of this interventional study is to learn about the combination of sotorasib and
stereotactic radiation therapy (SBRT) in patients with metastatic non-small cell lung cancer
(NSCLC) with KRASG12C mutations. The main question it aims to answer is:
• can SBRT be safely delivered in patients treated with sotorasib
Participants will be treated with sotorasib for an 8-week-induction period and if the patient
has stable disease or partial response, 1-3 of the remaining lesions will be irradiated with
SBRT and sotorasib will then be contiuned after irradiation. The patients will then be
followed and evaluated for toxicity to identify if grade 3-5 toxicity attributed to SBRT
occurs within 6 months post SBRT. Tumour effects measured according to RECIST v1.1 will also
be evaluated.